Literature DB >> 7681856

Acne fulminans: report of clinical findings and treatment of twenty-four patients.

S L Karvonen1.   

Abstract

BACKGROUND: Acne fulminans is an ulcerative form of acne with an acute onset and systemic symptoms. It most commonly affects adolescent boys.
OBJECTIVE: Clinical and laboratory findings and treatment results of patients with acne fulminans were reviewed to obtain a better understanding of the clinical course and outcome of the disease.
METHODS: Data of patients with severe acne were collected from the Dermatology Departments of Finnish hospitals during the years 1970 to 1991.
RESULTS: Twenty-four patients with acne fulminans are described. All patients had ulcerative acne with acute onset. In 22 patients acne was associated with high fever for at least 1 week. All patients had musculoskeletal pain. Increased uptake in bone scan or radiographic findings compatible with an infectious origin were detected in 17 patients. Eight patients were treated with antibiotics alone, but the response was poor; three patients had a relapse of musculoskeletal symptoms. Ten patients were given systemic steroids in addition to antibiotics. In this group the response was rapid, but acne and musculoskeletal symptoms tended to relapse when the steroid dosage was reduced. Four patients were treated with a combination of antibiotics, systemic steroids, and isotretinoin; all responded well, but one of these patients also had a relapse.
CONCLUSION: Musculoskeletal symptoms are common in patients with acne fulminans. Systemic steroid treatment rapidly controls the skin lesions and systemic symptoms. The duration of steroid treatment should be 2 to 4 months to avoid relapses. Therapy with isotretinoin, antibiotics, or both was often combined with steroids, but the role of these agents is still uncertain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681856     DOI: 10.1016/0190-9622(93)70076-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  The use of isotretinoin in acne.

Authors:  Alison Layton
Journal:  Dermatoendocrinol       Date:  2009-05

Review 2.  [Clinical variants of acne].

Authors:  T Jansen; S Grabbe; G Plewig
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

Review 3.  Guidelines for the management of acne vulgaris in adolescents.

Authors:  Victoria Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 4.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 5.  Acne. A review of optimum treatment.

Authors:  N L Sykes; G F Webster
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

6.  Hepatitis B, interferon, and acne fulminans in a young girl.

Authors:  Sandeep Arora; Ajay Malik; Dharmendra Kumar; Neha Sodhi
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr

7.  Successful Treatment of Facial Acne Fulminans: Antimicrobial Agents and Oral Prednisolone as Promising Regimes.

Authors:  Amir Hossein Siadat; Anis Bostakian; Bahareh Abtahi-Naeini; Masoom Shahbazi
Journal:  Case Rep Dermatol Med       Date:  2017-03-27

8.  Acne fulminans associated with lymecycline intake: a case report.

Authors:  Bruno Gualtieri; Annalisa Tonini; Salvatore Panduri; Andrea Chiricozzi; Marco Romanelli
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-08-03

9.  Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case.

Authors:  Claudio Marasca; Gabriella Fabbrocini; Luisa Abategiovanni; Elisa Camela; Mariateresa Nocerino; Adriana Di Guida; Gaia De Fata Salvatores
Journal:  Skin Appendage Disord       Date:  2021-01-21

10.  Pseudo-acne fulminans associated with oral isotretinoin.

Authors:  Luciana Rosa Grando; Oriete Gerin Leite; Tania Ferreira Cestari
Journal:  An Bras Dermatol       Date:  2014 Jul-Aug       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.